Ali Motazedian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Motazedian has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Azevedo
Storm Therapeutics, Cambridge, UK
61 shared publications - Andrea Gillespie
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
61 shared publications - Andrew A. Guirguis
Peter MacCallum Cancer Centre, Melbourne, Australia
61 shared publications - Benjamin J. Blyth
Models of Cancer Translational Research Centre, Research Division, Peter MacCallum Cancer Centre, 305 Grattan St., Melbourne, VIC 3000, Australia
61 shared publications - Brian Liddicoat
Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
61 shared publications - Byron Andrews
Storm Therapeutics Ltd, Cambridge, United Kingdom
61 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Co-culture assays + human PBMC data
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Co-culture assays + human PBMC data
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
PDL1 expression + STM3006 pharmacokinetic studies
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
PDL1 expression + STM3006 pharmacokinetic studies
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Proliferation + Apoptosis assays
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Proliferation + Apoptosis assays
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Gene expression changes + pathways
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Gene expression changes + pathways